OverT Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

OverT Bio is a private, pre-clinical stage biotech founded in 2021, headquartered in San Diego, CA, with a secondary office in New York, NY. The company is developing a differentiated platform that integrates AI-driven functional genomics, multimodal receptor design, and gamma delta T cells to create off-the-shelf cell therapies targeting solid tumors. With a lead program, OVT-101, anticipated to enter first-in-human trials in H1 2027, OverT aims to overcome key challenges in solid tumor treatment such as immunosuppression, poor T cell persistence, and manufacturing scalability. The company is backed by venture capital and strategic collaborators.

OncologySolid Tumors

Technology Platform

Integrated platform combining AI-powered, genome-scale functional genomics to discover novel T cell programming genes, multimodal receptor design, and gamma delta T cell biology to create off-the-shelf, allogeneic cell therapies for solid tumors.

Opportunities

The massive, unmet need in solid tumor treatment represents a multi-billion dollar market.

Success with its off-the-shelf, scalable model could enable broad patient access and superior commercial economics compared to autologous therapies.

The AI-driven discovery platform also offers potential for generating valuable intellectual property and future pipeline candidates or partnership opportunities.

Risk Factors

High technical risk integrating novel AI, biology, and manufacturing approaches; clinical risk in first-in-human trials for a complex therapy; and financial risk as a pre-revenue company requiring significant future capital raises in a competitive funding landscape.

The allogeneic solid tumor cell therapy space is also becoming increasingly crowded.

Competitive Landscape

OverT competes in the rapidly evolving allogeneic cell therapy space for solid tumors, facing companies like Allogene, Caribou Biosciences, Adicet Bio, and others using alpha-beta T cells, NK cells, or gamma delta T cells. Its differentiation lies in the systematic, AI-powered discovery of genetic programs to enhance cell function, combined with its focus on gamma delta T cell biology.

More companies in Cell & Gene Therapy →More companies in United States →